ethyl
first
prototyp
conform
restrict
analog
umifenovir
prepar
use
onepot
method
undergon
antivir
studi
ph
br
oh
nme
eto
c
hcl
h
time
umifenovir
author
medicin
use
number
countri
due
absenc
clear
knowledg
regard
biolog
target
addit
exist
technolog
prepar
medicin
two
mark
drawback
first
stage
bromin
ethyl
occur
low
regioselect
result
appear
polybromin
admixtur
commerci
product
second
concern
use
toxic
thiophenol
remov
trace
wast
water
present
particular
problem
correspond
address
email
kholstaedt
yandexru
rega
institut
medic
research
minderbroedersstraat
leuven
b
belgium
email
janbalzarini
regakuleuvenb
jointstock
compani
pharm
synthesi
build
kabelnaya
st
moscow
russia
email
evseviu
mailru
aim
work
creation
debromin
bioisoster
analog
umifenovir
sch
fragment
separ
indol
benzen
ring
chang
ring
replac
target
introduct
conform
rigid
link
give
possibl
fix
mutual
posit
nuclei
molecul
base
compar
activ
two
pair
diastereom
individu
enantiom
possibl
structur
pharmacophor
put
forward
case
umifenovir
result
chang
interact
model
potenti
biolog
target
conform
mobil
thiomethylen
link
induc
fit
model
vicin
substitut
cyclopropyliden
fragment
lock
key
model
approach
success
use
target
design
inhibitor
introduct
fragment
molecular
structur
avoid
use
thiophenol
synthesi
preserv
distanc
aromat
heteroaromat
ring
signific
degre
imit
electron
structur
thiomethylen
fragment
known
extent
within
scope
work
obtain
ethyl
onepot
reaction
ethyl
propano
methylammonium
acet
absolut
ethanol
start
prepar
reaction
meldrum
acid
subsequ
ethanolysi
acyl
product
initi
experi
convert
enaminoest
use
nenitzescu
reaction
method
report
ethyl
phenylsulfanyl
butano
fail
target
compound
obtain
trace
amount
main
product
due
aminolysi
ethoxycarbonyl
group
product
hunsdieck
cleavag
antivir
studi
compound
obtain
infect
cell
line
carri
use
umifenovir
antivir
medic
extern
standard
accord
literatur
method
compar
data
antivir
activ
studi
compound
given
tabl
sampl
carri
biolog
investig
initi
dissolv
aqueou
dmso
umifenovir
use
hydrochlorid
monohydr
compound
free
base
evid
tabl
neither
umifenovir
conform
rigid
analog
show
mark
antivir
activ
test
time
compound
prove
less
cytotox
compar
umifenovir
data
tabl
show
neither
umifenovir
conform
rigid
analog
exhibit
antivir
activ
studi
concentr
rang
howev
umifenovir
show
mark
cytotox
data
obtain
activ
umifenovir
toward
respiratori
syncyti
viru
disagre
literatur
data
mic
cytotox
concentr
substanc
live
cell
remain
visual
assess
use
microscopi
colorimetr
assess
use
photoelectrocolorimet
tabl
fulli
agre
literatur
data
sinc
umifenovir
condit
show
inhibitori
activ
rel
parainfluenza
viru
mic
data
tabl
show
toxic
umifenovir
exce
ethyl
one
order
mcc
versu
antivir
activ
reveal
either
compound
concentr
rang
studi
tabl
appar
umifenovir
compound
show
clear
cytotox
properti
rel
cocker
spaniel
hepatocyt
mcc
respect
cc
valu
unexpectedli
found
none
compound
possess
antivir
properti
toward
influenza
virus
influenza
b
viru
concentr
sinc
umifenovir
condit
previous
report
suppress
replic
influenza
viru
mic
time
obtain
data
contradict
inform
regard
abil
umifenovir
suppress
replic
influenza
influenza
b
virus
mic
valu
respect
note
studi
rel
influenza
virus
remantadin
show
markedli
greater
activ
umifenovir
also
contradict
literatur
data
henc
propos
synthesi
ethyl
conveni
onepot
method
prepar
first
prototyp
conform
restrict
umifenovir
analog
view
absenc
antivir
activ
obtain
compound
rang
studi
separ
individu
enantiom
pure
state
carri
inconsist
previou
evid
literatur
reveal
cours
biolog
studi
known
compound
confirm
need
wider
investig
relationship
chemic
structur
antivir
activ
seri
compound
flow
rate
hplc
analys
mlmin
detector
uv
nm
elsd
massspectrometr
analysi
use
electrospray
ioniz
element
analysi
carri
vario
el
cube
apparatu
halogen
content
determin
combust
sampl
materi
flask
fill
oxygen
use
visual
mercurometr
titrat
alkalin
hydrogen
peroxid
solut
absorb
separ
determin
chlorid
anion
carri
argentometr
method
melt
point
measur
capillari
method
use
buchi
apparatu
heat
rate
correct
valu
given
tlc
carri
merck
alufolien
kieselgel
f
visual
uv
light
nm
column
chromatographi
use
alfa
aesar
silica
gel
size
mm
mesh
synthes
use
alfa
aesar
acro
organ
chemic
reagent
solvent
solvent
dri
standard
method
antivir
studi
carri
use
method
cell
coloni
made
avail
cathol
univers
leuven
belgium
ethyl
dimethylamino
phenylsulfanyl
hydrochlorid
monohydr
umifenovir
prepar
previous
report
method
product
properti
previous
report
literatur
given
mp
decomp
mp
later
data
author
mp
given
characterist
valu
major
compound
content
hplc
elsd
ethyl
propano
solut
anhydr
ch
cl
prepar
g
mmol
method
use
ch
cl
ml
place
phme
ad
dropwis
stir
cool
ice
bath
solut
meldrum
acid
g
mmol
ipr
net
ml
g
mmol
absolut
ch
cl
ml
reaction
mixtur
left
overnight
room
temperatur
pour
onto
mixtur
crush
ice
g
conc
hcl
ml
organ
phase
separ
wash
n
hcl
ml
water
ml
dri
mgso
filtrat
desicc
solvent
remov
reduc
pressur
residu
treat
activ
carbon
g
absolut
etoh
ml
mixtur
reflux
protect
moistur
ga
evolut
ceas
h
product
filter
solvent
distil
residu
dissolv
ch
cl
ml
wash
aqueou
nahco
solut
ml
water
ml
dri
mgso
dri
solut
filter
filtrat
evapor
residu
distil
reduc
pressur
yield
calcul
g
colorless
oil
bp
mm
hg
mm
hg
ethyl
solut
menh
anhydr
etoh
ml
mmol
menh
treat
glacial
acoh
ml
g
mmol
g
mmol
ester
g
mmol
dissolv
absolut
etoh
ml
mixtur
obtain
reflux
h
solvent
distil
residu
dissolv
etoac
ml
wash
water
ml
satur
aqueou
nacl
solut
ml
dri
mgso
product
filter
silica
gel
ad
g
obtain
mixtur
evapor
dryness
product
absorb
silica
gel
transfer
chromatograph
column
target
product
purifi
graviti
elut
silica
gel
column
mm
etoac
hexan
gradient
eluent
fraction
contain
target
product
combin
evapor
reduc
pressur
residu
tritur
et
filter
dri
constant
weight
yield
g
colorless
crystal
mp
r
f
etoacpetroleum
ether
fraction
major
compound
content
hplc
uv
r
min
h
nmr
spectrum
mhz
cdcl
work
carri
financi
support
russian
foundat
basic
research
grant
